^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Bladder Cancer
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor) +
    Padcev (enfortumab vedotin-ejfv) (Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    04/25/2023
    Excerpt:
    Bladder Cancer….Cisplatin ineligible, first-line therapy for locally advanced or metastatic disease….Preferred regimen:...pembrolizumab and enfortumab vedotin-ejfv